Market Access

How medicines move from regulatory approval to patient availability. Covers pricing, reimbursement, HTA processes, and the strategic decisions that determine whether a drug actually reaches the people it was developed for.

Market Access

Jul 21, 2026

•

7 min read

Europe's complacency problem

My latest guest on The Pharma Perspective, Neil Grubert, needs no introduction. When we talked about drug pricing, he told me the danger he sees is "a certain level of complacency in Europe": the belief that every important medicine reaches us sooner or later. We still count on it, even as MFN, the EU's new launch obligation, and the rise of the Chinese industry pull it apart.

Mirko von Hein

Training

You can't out-study a decade in a weekend

Jul 7, 2026

•

5 min read

You can't out-study a decade in a weekend

If you moved into HEOR from a clinical, stats or consulting background, the job expects you to know what specialists spent ten years learning. Here's the structured route I built so you don't have to piece it together project by project.

Mirko von Hein

Training

100 videos in, here's the whole field in two minutes

Jun 30, 2026

•

3 min read

100 videos in, here's the whole field in two minutes

For my 100th video I tried to fit all of HEOR into two minutes. It's a fast tour of the same 12 steps the Roadmap is built on, and a quick way to see where you'd land.

Mirko von Hein

Career Advice

The map I wish I'd had on day one [Full HEOR Roadmap]

Jun 23, 2026

•

4 min read

The map I wish I'd had on day one [Full HEOR Roadmap]

I mapped the 120 capabilities that define excellence in HEOR, in the order they're best learned. It's free, and you can score yourself against the whole field in about ten minutes.

Mirko von Hein

Tools & Productivity

Five free resources every health economist should bookmark

Jun 2, 2026

•

5 min read

Five free resources every health economist should bookmark

The tools I reach for most, what justifies each one, and the "gotcha" to watch out for.

Mirko von Hein

Behind-the-scenes

May 11, 2026

•

2 min read

I've quit pharma. Am I mad?

Why I left Gilead, what Von Hein Consulting does, and what doesn't change for this newsletter.

Mirko von Hein

Tools & Productivity

You're Doing Expert Elicitation Wrong (And So Was I)

Mar 23, 2026

•

3 min read

You're Doing Expert Elicitation Wrong (And So Was I)

What defensible expert elicitation actually looks like — and a tool that makes it possible

Mirko von Hein

Market Access

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

Feb 16, 2026

•

6 min read

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.

Mirko von Hein

Market Access

Europe's complacency problem

You can't out-study a decade in a weekend

100 videos in, here's the whole field in two minutes

The map I wish I'd had on day one [Full HEOR Roadmap]

Five free resources every health economist should bookmark

I've quit pharma. Am I mad?

You're Doing Expert Elicitation Wrong (And So Was I)

The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?

The HEOR Intel You Actually Need

Tracking what matters in HEOR, market access, and pharma consulting for your career success